If Rule 702 is supposed to keep unreliable expert opinions out, this decision raises a fair question: how many gaps are too many? In In re Covidien Hernia Mesh Products Liability Litigation, 2026 WL 1129617 (D. Mass. Apr. 27, 2026), the court considered a familiar lineup of expert opinions—general causation, specific causation, alternative design, and warnings. The outcome is mixed. Most of plaintiff’s expert’s opinions survive. But not all.

Plaintiff underwent emergency hernia repair surgery and received defendant’s surgical mesh, a polyester textile with a porcine collagen and glycerol coating designed to prevent tissue attachment during healing. Three years later, plaintiff required another surgery to repair a recurrent hernia and bowel obstruction. During that procedure, the surgeon found a portion of plaintiff’s bowel “stuck tightly” to the prior mesh. Id. at *3.  Plaintiff’s theory, offered via a general surgery expert, is that the polyester triggers a chronic inflammatory response, and the collagen barrier—represented to last “less than 1 month”—actually degrades too rapidly, allowing adhesions to form and leading to complications like obstruction and recurrence. Id. at *2-3.

The primary attack on general causation focused on the expert’s reliance on animal studies while largely excluding human clinical data. And while the court acknowledged that opinions that rely on animal studies should be “scrutinized” due to the difficulty in extrapolating to humans, it allowed it here, especially given the ethical limitations on conducting human studies:

testing the barrier’s resorption in humans in the period immediately following a hernia repair would require reopening patients. Given this ethical limitation, animal studies and anecdotal case reports are a reliable basis for reaching a scientific conclusion about the resorption period of the barrier.

Id.  at *8.

That’s a fairly narrow, case-specific ruling which was bolstered in the court’s opinion by the fact that the studies the expert relied on were conducted by the defendant itself. Even though that says little about whether the expert reliably extrapolated from those studies to his ultimate conclusions.

The more notable move comes next. The court admitted that plaintiff’s expert lacked human clinical data on inflammatory response and could not clearly explain how his animal-based conclusions translated to humans. Id. at *9. Ordinarily, that would be a problem for the proponent of the testimony. Here, it wasn’t. Because defendant did not cite product-specific clinical studies affirmatively disproving the expert’s theory, the court allowed the opinion to stand. Id. That framing effectively flips the burden. Instead of requiring plaintiff to demonstrate reliability, the court faulted defendant for not filling the gaps.

The same dynamic appears in the court’s treatment of contrary clinical data. Defendant argued the expert cherry-picked his data by ignoring product-specific studies that showed no increased rate of relevant complications. Because plaintiff’s expert dismissed those studies as having “limitations,” the court found defendant’s argument went to weight, not admissibility. Leaving cross-examination—rather than Rule 702—to do the work. Id.

The court also admitted the expert’s specific causation opinion based on a differential diagnosis. On the “rule in” side, the expert pointed to the presence of “dense” adhesions observed during the explant surgery years later as support for his theory that adhesions began forming shortly after implantation due to premature barrier degradation. That was enough for the court. Id. at *10.

On the “rule out” side, the burden of proof was again flipped. Defendant identified two obvious alternative causes: the urgent nature of the surgery and the surgical technique used—both known risk factors for recurrence. But instead of requiring the expert to meaningfully rule them out, the defendant was required to “offer data” to rule them in.  Id. at *11. The result is a differential diagnosis that does not do much ruling out, yet still survives.

If the court was permissive on causation, it was not on design defect. Plaintiff’s expert offered two purported safer alternatives: a different material and a different product. That was essentially it. No comparative analysis. No discussion of risks and benefits. No methodology tying the alternatives to a safer outcome. That, the court held, is classic ipse dixit—and inadmissible. Plaintiff’s attempt to rehabilitate the opinion through attorney argument in briefing came too late and in the wrong form. Without support in an expert report, deposition, or affidavit, the expanded theories could not be considered. Id. at *12-13.

Finally, the court allowed the expert to testify about warning adequacy from a surgeon’s perspective. A practicing physician can opine on whether warnings communicate sufficient information for clinical decision-making. But the expert cannot offer legal conclusions about adequacy under the law. Nor is he required to opine on warning causation—that is, whether a different warning would have changed the treating surgeon’s conduct. Id. at *13-14.

Taken as a whole, the decision reads less like strict gatekeeping and more like gap tolerance. The court repeatedly acknowledges analytical shortcomings—missing data, unexplained extrapolations, incomplete differential diagnosis—but treats them as fodder for cross-examination rather than grounds for exclusion. In doing so, it edges toward placing the burden on defendants to disprove opinions that plaintiffs have not fully substantiated. Fortunately, the alternative design ruling cuts the other way. However far plaintiff’s causation opinions are allowed to go, design defect claims still require evidence of a feasible, safer alternative supported by a reliable methodology. Without that cornerstone, plaintiff’s design defect theory may have a short shelf life.